First-Generation TRK Inhibitors: Clinical Evidence and Indications

Decera Clinical Education Oncology Podcast · Oct 15, 2021 · 14m

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:

Basket trials leading to FDA approvals of larotrectinib and entrectinib

Current pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLC

Sequencing treatment with TRK inhibition in patients with solid tumors

Clinically relevant similarities and differences between…